GeoVax Labs, Inc. New financials
$0.3520+1.82%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $2.5M | $4.0M | $0.00 | $81.5K | $385.5K | $1.8M |
| Gross profit | $2.5M | $4.0M | $0.00 | $81.5K | $385.5K | $1.8M |
| Gross margin | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% |
| Operating income | -$21.6M | -$25.1M | -$26.7M | -$14.0M | -$18.7M | -$2.8M |
| Net income | -$21.5M | -$25.0M | -$26.0M | -$14.0M | -$18.6M | -$3.0M |
| Net margin | −862.3% | −632.0% | — | −17198.3% | −4817.2% | −162.2% |
| Diluted EPS | $-22.40 | $-120.46 | $-357.25 | $-309.75 | $-1140.00 | $-802.50 |
| EBITDA | -$21.6M | -$25.0M | -$26.7M | -$14.0M | -$18.7M | -$2.8M |
| Operating cash flow | -$21.5M | -$24.7M | -$25.2M | -$19.0M | -$11.2M | -$2.8M |
| Free cash flow | -$21.5M | -$24.7M | -$25.2M | -$19.2M | -$11.2M | -$2.9M |
| Diluted shares | 1.0M | 0.2M | 0.1M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.1M | $5.5M | $6.5M | $27.6M | $11.4M | $9.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $198.1K |
| Total assets | $6.3M | $8.2M | $9.3M | $31.3M | $11.8M | $10.4M |
| Total liabilities | $2.5M | $3.1M | $3.5M | $4.7M | $7.4M | $825.0K |
| Shareholders' equity | $3.8M | $5.0M | $5.8M | $26.6M | $4.4M | $9.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology